Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patients who proved H. pylori infection following three methods~  * Positive rapid urease test~ * Histologic evidence of H. pylori by modified Giemsa staining~ * Positive stool Antigen Test~Exclusion Criteria:~* Patients who received eradication therapy for H. pylori infection, previously~* H. pylori eradication failure because of poor compliance~* The administration of antibiotics or the consumption of bismuth salts within 4 weeks or the administration of a proton pump inhibitor (PPI) within 2 weeks~* Advanced gastric cancer or other malignancy~* Abnormal liver function or liver cirrhosis~* Abnormal renal function or chronic kidney disease~* Other severe concurrent diseases~* Previous allergic reactions to the study drugs~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tavanex & Nexium & Tinafas (Type: EXPERIMENTAL): Patients will receive Nexium (Esomeprazole) 40 mg daily and Tinafas (Tinidazole) 1 g daily and Tavanex (Levofloxacin) 500 mg daily for 14 days
- Lanzol & Klacid &Iramox (Type: ACTIVE_COMPARATOR): Patients will receive Lanzol (lansoprazole) 30 mg twice daily and Klacid (clarithromycin) 500 mg twice daily and Iramox (amoxicillin) 1 g twice daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).